Do MSI-L sporadic colorectal tumors develop through "mild mutator pathway"?

Am J Clin Oncol. 2006 Aug;29(4):364-70. doi: 10.1097/01.coc.0000221428.35366.cb.

Abstract

Background: The mutator pathway implied in the development of colorectal cancer (CRC) is characterized by microsatellite instability (MSI). MSI tumors can be subdivided according to the level of instability: MSI-H (high), MSI-L (low) or stable MSS. MSI-H CRC displays a well described distinct phenotype, but the true biologic significance of MSI-L is still uncertain. The objective of this study was to further clarify if the MSI-L phenotype could reflect a distinct pathway of tumor development with a different clinical behavior.

Methods: We analyzed the clinicopathological and genetic variables of 156 patients with sporadic CRC in relation with the level of MSI of the tumors.

Results: We have found that MSI-L tumors are someway in the middle of MSI-H and MSS CRC, as they share some features with each of the other 2 subgroups: left side location, lower incidence of LOH at MSH2 as MSS and Dukes B (stage II TNM) like MSI-H. Moreover, MSI-L tumors show higher incidence of KRAS mutations.

Conclusion: We believe that MSI-L tumors could be considered a distinct phenotype that develops through a "mild mutator pathway."

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • Female
  • Humans
  • Male
  • Microsatellite Repeats*
  • Middle Aged
  • MutS Homolog 2 Protein / genetics
  • Mutation
  • Phenotype
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins p21(ras)
  • Survival Analysis
  • ras Proteins

Substances

  • KRAS protein, human
  • Proto-Oncogene Proteins
  • MSH2 protein, human
  • MutS Homolog 2 Protein
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins